SCHEMBL4900360

SCHEMBL4900360

C=Cc1ccc(C(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.67
LMNA P02545 3/20 0.67
SRD5A2 P31213 2/20 0.57
MAPT P10636 3/20 0.50
HTT P42858 4/20 0.48
NPSR1 Q6W5P4 3/20 0.48
PKM P14618 2/20 0.48
ATM Q13315 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 2/20 0.48
NLRP1 Q9C000 1/20 0.48
MEN1 O00255 1/20 0.48
NTSR1 P30989 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44
RAB9A P51151 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38133 0.89 ALDH1A1 (0.58) ALDH1A1LMNASRD5A2MAPTHTT
SCHEMBL9717505 0.86 MAPT (0.55) ALDH1A1LMNAMAPTHTTNPSR1
Bicarbonate SCHEMBL3208132 0.85 ALDH1A1 (0.52) ALDH1A1LMNASRD5A2MAPTHTT
Acetic Acid SCHEMBL28854711 0.83 ALDH1A1 (0.50) ALDH1A1LMNAMAPTHTTNPSR1
SCHEMBL463760 0.82 TDP1 (0.52) ALDH1A1LMNAMAPTHTTNPSR1
SCHEMBL52200 0.82 ALDH1A1 (1.00) ALDH1A1LMNASRD5A2MAPTHTT
SCHEMBL822185 0.82 ALDH1A1 (1.00) ALDH1A1LMNASRD5A2MAPTHTT
SCHEMBL679555 0.82 ALDH1A1 (0.69) ALDH1A1MAPTNPSR1SMN1; SMN2MEN1
SCHEMBL14911 0.82
SCHEMBL39787 0.81 ALDH1A1 (0.61) ALDH1A1LMNASRD5A2MAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110563918-A Preparation method of modified grafted polyurethane resin 福建国邦新材料有限公司 2019-12-13 CN claimed
CN-110563918-A Preparation method of modified grafted polyurethane resin 福建国邦新材料有限公司 2019-12-13 CN disclosed
CN-110563918-A Preparation method of modified grafted polyurethane resin 福建国邦新材料有限公司 2019-12-13 CN disclosed
US-7968539-B2 reversed chloroquines; to treat chloroquine resistant/sensitive malaria parasites; N'-(7-Chloro-quinolin-4-yl)-N-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-N-methyl-propane-1,3-diamine STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) 2011-06-28 US disclosed
US-20080188462-A1 Quinoline Derivatives And Uses Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-08-07 US disclosed
US-20080003288-A1 Responsive microgel and methods related thereto SUPRATEK PHARMA INC. (CA) 2008-01-03 US disclosed
US-7204997-B2 Responsive microgel and methods related thereto SUPRATEK PHARMA INC. (CA) 2007-04-17 US disclosed
EP-1478403-A1 RESPONSIVE MICROGEL AND METHODS RELATED THERETO SUPRATEK PHARMA, INC. (CA) 2004-11-24 EP disclosed
US-20040147682-A1 Transparent block copolymers and production thereof ATOFINA RESEARCH (BE) 2004-07-29 US disclosed
EP-1408061-A1 Process for the production of a transparent copolymer ATOFINA Research (BE) 2004-04-14 EP disclosed
US-20030152623-A1 Responsive microgel and methods related thereto SUPRATEK PHARMA INC. (CA) 2003-08-14 US disclosed
WO-2003063909-A1 RESPONSIVE MICROGEL AND METHODS RELATED THERETO SUPRATEK PHARMA INC. (US) 2003-08-07 WO disclosed
EP-0910351-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-28 EP disclosed
EP-0907666-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-14 EP disclosed
WO-1997049736-A2 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed
WO-1997049387-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed
EP-0422236-B1 PRODUCTION OF ALKENYLBENZOPHENONE NIPPON PETROCHEMICALS CO LTD (JP) 1995-06-14 EP disclosed
EP-0422236-A1 PRODUCTION OF ALKENYLBENZOPHENONE NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1991-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188462-A1 Quinoline Derivatives And Uses Thereof RECQL, QARS1, QTRT1 ALDH1A1 3478/4885LMNA 3368/4885SRD5A2 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.